AbbVie’s New Study on Parkinson’s Treatment: What Investors Need to Know

Abbvie (ABBV) announced an update on their ongoing clinical study.

AbbVie has announced a new clinical study titled ‘A Global Real-World Evidence Study on the Effectiveness and Safety/Tolerability of Foslevodopa/Foscarbidopa in Patients Earlier Within Advanced Parkinson’s Disease.’ The study aims to evaluate the effectiveness and safety of Foslevodopa/Foscarbidopa in treating adults with advanced Parkinson’s Disease. This study is significant as it seeks to provide real-world evidence on the drug’s impact on quality of life outcomes in patients.

The intervention being tested is Foslevodopa/Foscarbidopa, an approved treatment for Parkinson’s Disease. The drug is administered via subcutaneous infusion, and the study will observe its effects under routine clinical practice conditions.

This observational study follows a cohort model with a prospective time perspective. Approximately 100 participants will be enrolled globally, receiving treatment as prescribed by their physicians. The primary purpose is to gather data on motor function and well-being through participant and caregiver questionnaires.

The study is set to begin on November 10, 2025, with the last update submitted on November 12, 2025. The primary completion and estimated completion dates are yet to be announced, marking the study as not yet recruiting.

For investors, this study could influence AbbVie’s stock performance by potentially validating the effectiveness of Foslevodopa/Foscarbidopa, thereby strengthening its market position in the Parkinson’s Disease treatment landscape. It may also affect investor sentiment positively if the results are favorable, especially in comparison to competitors in the neurological treatment market.

The study is ongoing, with further details available on the ClinicalTrials portal.

To learn more about ABBV’s potential, visit the Abbvie drug pipeline page.